STOCK TITAN

BioNxt Solutions Inc. Announces Non-Brokered Private Placement of Units

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
private placement

BioNxt Solutions (BNXTF) announced a non-brokered private placement targeting gross proceeds of up to $2,500,000 through the sale of units.

The offering comprises up to 10,000,000 units at $0.25 each, with one common share and one share purchase warrant per unit. Each warrant permits purchase of an additional share at $0.50 for twenty-four months from closing. BioNxt intends to use net proceeds for European-based research and development, including its planned human clinical study, plus working capital and general corporate purposes.

Eligible finders may receive cash fees of up to 8.0% on qualifying proceeds and warrants equal to up to 8.0% of units sold, exercisable at $0.50 for twenty-four months from issuance. Closing may occur in tranches and remains subject to conditions, including Canadian Securities Exchange acceptance.

Loading...
Loading translation...
2 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 5 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate point. Forward-looking: it has not happened yet and may not happen.Planned private placement targets up to $2,500,000 in gross proceeds. 8.1% of market cap
  • Minor point. Forward-looking: it has not happened yet and may not happen.BioNxt intends proceeds to fund European research and development, including its planned human clinical study.

Negative

  • Moderate point. Forward-looking: it has not happened yet and may not happen.Up to 10,000,000 units at $0.25 each would issue one common share and one warrant per unit.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Unit warrants permit additional shares at $0.50 for twenty-four months from closing, creating potential further dilution.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Cash finder's fees may reach 8.0% of proceeds from subscribers directly introduced by eligible finders.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Finder's warrants may equal up to 8.0% of units sold, exercisable at $0.50 for twenty-four months from issuance.
  • Minor pointOffering closing remains subject to Canadian Securities Exchange acceptance and other conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

VANCOUVER, BC / ACCESS Newswire / November 16, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce a non-brokered private placement of up to 10,000,000 units of the Company (the "Units") at a price of $0.25 per Unit for gross proceeds of up to $2,500,000 (the "Offering"). Each Unit will be comprised of one common share in the capital of the Company (a "Share") and one Share purchase warrant (each whole warrant, a "Warrant"). Each Warrant will entitle the holder thereof to acquire one additional Share (a "Warrant Share") at a price of $0.50 per Warrant Share for a period of twenty-four (24) months from the date of closing (the "Closing Date").

The Company intends to use the net proceeds from the Offering for conducting the Company's European-based research and development operations, including its planned human clinical study, and for working capital and general corporate purposes.

In connection with the Offering, the Company may pay cash finder's fees of up to 8.0% of the gross proceeds raised by the Company from the sale of Units to subscribers directly introduced to the Company by eligible finders. In addition, the Company may issue to eligible finders an aggregate number of non-transferable finder's warrants (each, a "Finder's Warrant") equal to up to 8.0% of the number of Units sold in the Offering. Each Finder's Warrant will entitle the holder to purchase one Share at an exercise price of $0.50 for a period of twenty-four (24) months from the date of issuance.

The Offering may close in tranches on one or more dates as the Company may determine. Closing of the Offering remains subject to a number of conditions, including the acceptance of the Canadian Securities Exchange ("CSE").

All securities issued in connection with the Offering will be subject to a statutory hold period of four months and one day following the Closing Date in accordance with applicable Canadian securities laws and policies of the CSE.

About BioNxt Solutions Inc.

BioNxt Solutions Inc. is a bioscience innovator focused on next‐generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin‐Film), Transdermal (Skin Patch), and Oral (Enteric‐Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity. With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient‐centric solutions that enhance treatment outcomes worldwide. BioNxt is listed on the Canadian Securities Exchange: BNXT, OTCQB Markets: BNXTF and trades in Germany under WKN: A3D1K3.

For more Company information, please visit https://bionxt.com/ or review its profiles on www.sedarplus.ca and on the Canadian Securities Exchange's website, www.thecse.com.

BioNxt Solutions Inc.

Hugh Rogers, CEO and Director
Email: info@bionxt.com
Phone: +1 604-250-6162

THE SECURITIES REFERRED TO IN THIS NEWS RELEASE HAVE NOT BEEN, NOR WILL THEY BE, REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "U.S. SECURITIES ACT"), AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS ABSENT U.S. REGISTRATION OR AN APPLICABLE EXEMPTION FROM THE U.S. REGISTRATION REQUIREMENTS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER FOR SALE OF SECURITIES, NOR A SOLICITATION FOR OFFERS TO BUY ANY SECURITIES IN THE UNITED STATES, NOR IN ANY OTHER JURISDICTION IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL. ("UNITED STATES" AND "U.S. PERSON" ARE AS DEFINED IN REGULATION S UNDER THE U.S. SECURITIES ACT).

Forward-Looking Information

This news release includes certain statements that may be deemed "forward-looking statements". All statements in this news release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Forward-looking information in this news release includes, without limitation, statements relating to the Offering and the use of proceeds raised in the Offering. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include including risks regarding market conditions, management's ability to manage and to operate the business, the development and advancement of Company's European operations, equity markets generally, the availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

SOURCE: BioNxt Solutions Inc.



View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much does BioNxt's private placement aim to raise, and what does each unit include?

BioNxt is offering up to 10,000,000 units at $0.25 per unit for gross proceeds of up to $2,500,000. Each unit includes one common share and one warrant to buy an additional share at $0.50 for twenty-four months from closing.

What hold period applies to securities issued in BioNxt's private placement?

All securities issued in connection with the offering are subject to a statutory hold period of four months and one day following the closing date, under applicable Canadian securities laws and Canadian Securities Exchange policies.

Keep reading